Thyroid Nodule Molecular Testing: Is It Ready for Prime Time?

Tahsin M. Khan; Martha A. Zeiger

doi:10.3389/fendo.2020.590128

Thyroid Nodule Molecular Testing: Is It Ready for Prime Time?

Research output: Contribution to journal › Review article › peer-review

Abstract

Cytologically indeterminate thyroid nodules remain a diagnostic and clinical challenge, and molecular testing has been advocated and advanced as a diagnostic modality to help guide treatment. While studies have expounded on the improved diagnostic certainty with these tests, data demonstrating meaningful clinical impact and supporting their routine use is still limited at best. In this review, we discuss the limitations regarding diagnostic accuracy, impact on surgical decision-making and outcomes, and cost-effectiveness of molecular testing. By highlighting the limitations of these tests, we aim to promote more thoughtful utilization of these tools in the management of thyroid nodules going forward.

Original language	English (US)
Article number	590128
Journal	Frontiers in Endocrinology
Volume	11
DOIs	https://doi.org/10.3389/fendo.2020.590128
State	Published - Oct 9 2020
Externally published	Yes

Keywords

diagnostic testing
indeterminate/suspicious thyroid nodule
management algorithm
molecular testing
thyroid cancer
thyroid surgery

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism

Access to Document

10.3389/fendo.2020.590128

Cite this

@article{91d50bff130c4993b086c778e862563e,

title = "Thyroid Nodule Molecular Testing: Is It Ready for Prime Time?",

abstract = "Cytologically indeterminate thyroid nodules remain a diagnostic and clinical challenge, and molecular testing has been advocated and advanced as a diagnostic modality to help guide treatment. While studies have expounded on the improved diagnostic certainty with these tests, data demonstrating meaningful clinical impact and supporting their routine use is still limited at best. In this review, we discuss the limitations regarding diagnostic accuracy, impact on surgical decision-making and outcomes, and cost-effectiveness of molecular testing. By highlighting the limitations of these tests, we aim to promote more thoughtful utilization of these tools in the management of thyroid nodules going forward.",

keywords = "diagnostic testing, indeterminate/suspicious thyroid nodule, management algorithm, molecular testing, thyroid cancer, thyroid surgery",

author = "Khan, {Tahsin M.} and Zeiger, {Martha A.}",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2020 Khan and Zeiger.",

year = "2020",

month = oct,

day = "9",

doi = "10.3389/fendo.2020.590128",

language = "English (US)",

volume = "11",

journal = "Frontiers in Endocrinology",

issn = "1664-2392",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Thyroid Nodule Molecular Testing

T2 - Is It Ready for Prime Time?

AU - Khan, Tahsin M.

AU - Zeiger, Martha A.

PY - 2020/10/9

Y1 - 2020/10/9

N2 - Cytologically indeterminate thyroid nodules remain a diagnostic and clinical challenge, and molecular testing has been advocated and advanced as a diagnostic modality to help guide treatment. While studies have expounded on the improved diagnostic certainty with these tests, data demonstrating meaningful clinical impact and supporting their routine use is still limited at best. In this review, we discuss the limitations regarding diagnostic accuracy, impact on surgical decision-making and outcomes, and cost-effectiveness of molecular testing. By highlighting the limitations of these tests, we aim to promote more thoughtful utilization of these tools in the management of thyroid nodules going forward.

AB - Cytologically indeterminate thyroid nodules remain a diagnostic and clinical challenge, and molecular testing has been advocated and advanced as a diagnostic modality to help guide treatment. While studies have expounded on the improved diagnostic certainty with these tests, data demonstrating meaningful clinical impact and supporting their routine use is still limited at best. In this review, we discuss the limitations regarding diagnostic accuracy, impact on surgical decision-making and outcomes, and cost-effectiveness of molecular testing. By highlighting the limitations of these tests, we aim to promote more thoughtful utilization of these tools in the management of thyroid nodules going forward.

KW - diagnostic testing

KW - indeterminate/suspicious thyroid nodule

KW - management algorithm

KW - molecular testing

KW - thyroid cancer

KW - thyroid surgery

UR - http://www.scopus.com/inward/record.url?scp=85094152357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094152357&partnerID=8YFLogxK

U2 - 10.3389/fendo.2020.590128

DO - 10.3389/fendo.2020.590128

M3 - Review article

AN - SCOPUS:85094152357

SN - 1664-2392

VL - 11

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

M1 - 590128

ER -

Thyroid Nodule Molecular Testing: Is It Ready for Prime Time?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this